Darwin Biotech Presents Phase 1 ALS Study Data at NEALS Meeting

Darwin Biotech presented randomized Phase 1 data for cell-free ALT001 and the design of a U.S. Phase 1/2 study. The Phase 1 study found ALT001 well tolerated, with early signals on function and NfL.